GMM Pfaudler LimitedQ1 FY27 Results & Financial Update

Pharma and peptide investments are strong in India and the US, and CRT orders recovered in China, whereas European markets remain slow and challenging particularly for chemicals.

Total debt stands at approximately INR 835 crores as of March 2026, with ongoing efforts to restructure the corporate framework across 24-25 entities to optimize borrowing costs and currency exposures.

Group CFO indicated a target steady-state tax rate of around 30% or slightly lower over the long term once organizational and debt restructuring concludes in 18 to 24 months.

Unlike Q1 FY26 where 30% of order intake comprised multi-year projects, the current order backlog is largely composed of projects with 10 to 12-month execution cycles, providing strong near-term revenue visibility for FY27.

HET secured EIL approvals for Duplex, Super Duplex, and air-cooled heat exchangers, and expanded further into power, nuclear, and fertilizer segments alongside Middle East oil and gas orders.

The company is optimizing its cost structure by utilizing low-cost engineering centers in Poland and India, alongside prior workforce reductions in the UK and Germany.

Management reaffirmed an aspirational long-term company EBITDA margin target of 15% or higher, focusing on turning around underperforming units and improving EBIT-to-PAT conversion through legal entity rationalization.

The company plans to repay approximately EUR 7 million of debt by the end of Q2 FY27 and expects to continuously reduce debt and leverage metrics over a 12 to 18-month timeframe via refinancing and group restructuring.

While declining to give specific quarterly financial guidance, management expects overall improvement across all businesses compared to the previous year, supported by robust order intake momentum heading into Q2.

Discussed recovery signs in pharma versus flat chemical markets, and questioned standalone margin dips which management attributed to HET product mix changes and organizational hiring investments.

Inquired about margin improvement timeframes and segment ROCE profiles; management noted that a few underperforming units are dragging down group averages while structural remediation is underway.

Asked about sales execution under the new structure and targeted debt levels; management highlighted a EUR 7 million repayment in Q2 and a multi-quarter structural deleveraging plan.

Queried the sustainability of pharma green shoots and PPT growth; management confirmed strong global traction in CDMO, peptides, and mixing systems with robust execution pipelines.

Asked about the exact share of 10-12 month executable backlog and long-term tax rates; management reiterated that the large majority of current orders fall into the 10-12 month window and target a 30% tax rate post-restructuring.

Queried one-off severance costs (confirmed none) and future employee cost escalation, which management plans to mitigate via GEC/GCC migration to India and Poland.

Asked for modeling assumptions on interest rates (6% to 7% based on SOFR/EURIBOR with hedging) and order intake trajectory supported by strong visibility.